Viking Therapeutics, Inc. (VKTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Viking Therapeutics reported revenue of $0. Net income was -$359.6M, or -$3.19 per diluted share. Operating activities generated -$278.7M of cash. At fiscal year end, Viking Therapeutics held $715.7M in total assets against $76.7M in total liabilities, including $165.8M of cash and equivalents.
Open the full interactive Viking Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Viking Therapeutics Key Stats
| Share Price | $26.65 |
|---|---|
| Market Cap | $3.10B |
| 52-Week Range | $26.29 – $42.13 |
| Shares Outstanding | 116.3 million (basic, 2026 Q2) |
Viking Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$42.7M | -$55.7M | -$70.4M | -$100.8M | -$150.9M | -$393.3M |
| Pre-Tax Income | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| Income Tax | $0 | $2,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net Income | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| Diluted EPS | -$0.54 | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 |
Viking Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$90.8M | -$157.7M | -$158.3M | -$128.0M |
| Diluted EPS | -$0.81 | -$1.40 | -$1.37 | -$1.10 |
Viking Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.1M | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M |
| Current Assets | $256.1M | $210.5M | $167.0M | $367.2M | $907.2M | $715.6M |
| Total Assets | $256.5M | $210.7M | $168.5M | $368.5M | $908.3M | $715.7M |
| Current Liabilities | $12.1M | $8.8M | $21.9M | $19.1M | $27.4M | $76.7M |
| Total Liabilities | $12.2M | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M |
| Shareholders' Equity | $244.3M | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M |
Viking Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$21.8M | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Cash From Investing | $41.6M | $38.0M | $54.8M | -$179.1M | -$553.4M | $341.4M |
| Cash From Financing | $950,000 | $6.9M | $4.2M | $271.4M | $612.5M | $76.4M |
Figures from Viking Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Viking Therapeutics financials page for every line item.
Viking Therapeutics Company Profile
| Ticker | VKTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001607678 |
Frequently Asked Questions
What was Viking Therapeutics' revenue in fiscal 2025?
Viking Therapeutics (VKTX) reported revenue of $0 for fiscal 2025.
What is Viking Therapeutics' annual revenue history?
Viking Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Viking Therapeutics' net income in fiscal 2025?
Viking Therapeutics reported net income of -$359.6M for fiscal 2025.
What was Viking Therapeutics' earnings per share (EPS) in fiscal 2025?
Viking Therapeutics' diluted EPS was -$3.19 for fiscal 2025 (adjusted for any later stock splits).
What was Viking Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Viking Therapeutics reported revenue of $0.
How many shares of Viking Therapeutics are outstanding?
Viking Therapeutics reported a weighted average of 116.3 million basic shares outstanding in 2026 Q2.
What is Viking Therapeutics' market cap?
Based on its latest closing price, Viking Therapeutics (VKTX) has a market capitalization of about $3.10B.
When does Viking Therapeutics' fiscal year end?
Viking Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Viking Therapeutics headquartered?
Viking Therapeutics lists its business address in San Diego, California in its SEC filings.